Company: NCEL
Filing Date: 2025-01-16
Form Type: 425
Source: 0001213900-25-004028
Chunk: 5

Company: NewcelX Ltd.
Filing Date: 2025-01-16
Form: 425
Chunk 5
---
 the SEC through the website maintained by the SEC
at http://www.sec.gov. Copies of the documents filed with the SEC by the Company will be available free of charge on NLS’s website
at www.nlspharma.com.

Participants in the Solicitation

NLS, Kadimastem, and certain of their respective directors and
executive officers may be deemed to be participants in the solicitation of proxies from NLS and Kadimastem shareholders in respect of
the proposed transaction. Information about the directors and executive officers of NLS, including a description of their direct or indirect
interests, by security holdings or otherwise, is set forth in NLS’s Annual Report on Form 20-F for the fiscal year ended December
31, 2023, which was filed with the SEC on May 15, 2024. Other information regarding the participants in the proxy solicitation and a description
of their direct and indirect interests, by security holdings or otherwise, will be contained in the proxy statement/prospectus and other
relevant materials to be filed with the SEC regarding the proposed merger when such materials become available. Investors should read
the proxy statement/prospectus carefully when it becomes available before making any voting or investment decisions. You may obtain free
copies of these documents from NLS Pharmaceutics using the sources indicated above.

NLS Contacts:

InvestorRelations@nls-pharma.com
www.nlspharma.com

Kadimastem Contacts:

Sarah Bazak, Investors relations

s.bazak@kadimastem.com

www.kadimastem.com, Social Media: Social Media: LinkedIn, X, Facebook, Instagram

<div align='center'>3</div>